|国家科技期刊平台
首页|期刊导航|中国医院用药评价与分析|阿替普酶联合早期肠内营养制剂用于急性脑梗死患者的效果观察

阿替普酶联合早期肠内营养制剂用于急性脑梗死患者的效果观察OACSTPCD

Efficacy of Alteplase Combined with Early Enteral Nutrition Preparation in the Treatment of Acute Cerebral Infarction

中文摘要英文摘要

目的:探讨阿替普酶联合早期肠内营养制剂用于急性脑梗死患者的作用效果.方法:选取2021 年1 月至2023 年6 月南通大学附属海安市人民医院收治的急性脑梗死患者 98 例,采用随机数字表法分为观察组和对照组,各 49 例.对照组患者在阿替普酶溶栓后给予早期常规自制鼻饲流质饮食治疗,观察组患者在阿替普酶溶栓后给予早期鼻饲肠内营养制剂治疗.比较两组患者的临床疗效、营养状况[前白蛋白(PA)、白蛋白(ALB)和总蛋白(TP)]、神经功能[美国国立卫生院卒中神经功能缺损评分量表(NIHSS)评分]、神经损伤标志细胞因子[血清神经元特异性烯醇化酶(NSE)、S100 钙结合蛋白β(S100β)和脑源性神经营养因子(BDNF)]水平、格拉斯哥结局评分(GOS)、颅内出血率和住院指标.结果:治疗后,观察组患者的总有效率显著高于对照组[83.7%(41/49)vs.65.3%(32/49)],差异有统计学意义(χ2=4.353,P<0.05).治疗后,观察组患者的PA水平(t=12.593,P<0.001)、ALB水平(t=4.583,P<0.001)、TP水平(t=4.497,P<0.001)、BDNF水平(t=4.619,P<0.01)和GOS评分(t=4.342,P<0.001)高于对照组,NIHSS评分(t=5.371,P<0.001)、NSE水平(t=4.342,P<0.001)和S100β水平(t=6.015,P<0.001)低于对照组,加强监护病房停留时间(t=4.358,P<0.001)、住院时间(t=6.509,P<0.001)短于对照组,上述差异均有统计学意义.对照组1 例患者出现无症状性脑出血,观察组无患者出现无症状性脑出血,两组患者均未出现症状性颅内出血;两组患者颅内出血率的差异无统计学意义(P>0.05).结论:阿替普酶联合早期肠内营养制剂对于减轻急性脑梗死患者神经损伤的疗效良好,还有助于促进患者营养状况和预后质量的改善,具有较好的临床应用价值.

OBJECTIVE:To probe into the clinical effect of alteplase combined with early enteral nutrition preparation on patients with acute cerebral infarction.METHODS:A total of 98 patients with acute cerebral infarction admitted into Hai'an People's Hospital Affiliated to Nantong University from Jan.2021 to Jun.2023 were selected to be divided into observation group and control group via random number table method,with 49 cases in each group.The control group was given early routine self-made nasal feeding liquid diet after alteplase thrombolytic therapy,while the observation group received early nasal feeding enteral nutrition preparation after alteplase thrombolytic therapy.The clinical efficacy,nutritional status indicators[prealbumin(PA),albumin(ALB)and total protein(TP)],neurological function[National Institutes of Health Stroke Scale(NIHSS)],neuro-impairment markers levels[serum neuron-specific enolase(NSE),S100 calcium binding protein β(S100β)and brain-derived neurotrophic factor(BDNF)],Glasgow outcome scores(GOS),intracranial hemorrhage rate and hospitalization indicators were compared between two groups.RESULTS:After treatment,the total effective rate of the observation group was significantly higher than that of control group[83.7%(41/49)vs.65.3%(32/49)],with statistically significant difference(χ2=4.353,P<0.05).After treatment,the PA level(t=12.593,P<0.001),ALB level(t=4.583,P<0.001),TP level(t=4.497,P<0.001),BDNF level(t=4.619,P<0.01)and GOS score(t=4.342,P<0.001)of the observation group were higher than those of the control group,the NIHSS score(t=5.371,P<0.001),NSE level(t=4.342,P<0.001)and S100β(t=6.015,P<0.001)of the observation group were lower than those of the control group,the ICU stay(t=4.358,P<0.001)and hospital stay(t=6.509,P<0.001)of the observation group were shorter than those of control group,all of the above differences were statistically significant.One patient in the control group developed asymptomatic cerebral hemorrhage,while no patient in the observation group developed asymptomatic intracerebral hemorrhage,no symptomatic intracranial hemorrhage occurred in both groups;the difference in intracranial hemorrhage rates between two groups was not statistically significant(P>0.05).CONCLUSIONS:Alteplase combined with early enteral nutrition preparation has significant efficacy in reducing nerve injury in patients with acute cerebral infarction,which also helps to promote the improvement of patients'nutritional status and prognostic quality,with good clinical application value.

王晶晶;葛春霞;孙青;姜新娣;陈小进

南通大学附属海安市人民医院神经内科,江苏 海安 226600南通大学附属医院神经内科,江苏 南通 226006

药学

阿替普酶营养制剂急性脑梗死肠内营养临床疗效

AlteplaseNutrition preparationsAcute cerebral infarctionEnteral nutritionClinical efficacy

《中国医院用药评价与分析》 2024 (006)

697-700,704 / 5

江苏省卫健委科研课题(No.Z2019042)

10.14009/j.issn.1672-2124.2024.06.013

评论